This review critically analyzes ligand-functionalized polymeric NPs for GBM therapy and discusses the integration of repurposed and off-label non-alkylating agents with nanocarrier engineering, focusing on non-alkylating agents as they are MGMT-independent candidates. This evidence concerns the gene MGMT and glioblastoma.